SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high December and fourth-quarter 2025 vehicle deliveries, meeting the high end of its guidance and nearing one million cumulative vehicles overall. This strong performance, coupled with China's extended EV purchase tax benefits favoring battery-swapping models, has ignited community discussions about potential Q4 profitability and a bright 2026 outlook for the multi-brand EV maker. Many investors are optimistic, comparing NIO's sales favorably against peers and anticipating significant upside despite recent price volatility.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its highly engaged community actively champions the "OG meme" narrative of Rage Comics, viewing it as the foundational "meme reset." This dedicated base is passionately building out an ecosystem with tools like RageMaker and RageGames, expressing strong conviction for significant long-term growth and widespread recognition as they aim to lead the next major meme coin cycle.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing high trading volume driven by news of a strategic manufacturing partnership to scale production of its fingerprinting drug screening reader. This announcement has ignited a fierce debate within the trading community, with many anticipating a short squeeze due to the stock's low float, while others express caution regarding potential dilution and pump-and-dump dynamics.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is trending as its community grapples with the impact of a recent dividend distribution, leading to widespread confusion and frustration over its sharp decline. Many investors are questioning why the 2x leveraged ETF is not tracking its underlying asset, SMCI, as expected, fueling concerns about decay and the potential for a reverse split. While some traders see the current suppressed levels as a buying opportunity, others warn of the significant volatility and risks inherent in such leveraged products.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending due to the definitive sale of its Bressner Technology subsidiary for $22.4 million, a strategic move by management to focus on its higher-growth Edge AI compute business and strengthen its balance sheet. The community is actively discussing this, alongside strong anticipation for an imminent multi-hundred-million dollar US Army situational awareness contract, seeing OSS as significantly undervalued within the defense and AI sectors.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after its relacorilant drug for Cushing's syndrome received a Complete Response Letter from the FDA, requesting additional efficacy evidence despite a successful pivotal trial, causing a sharp stock decline. Many investors view this over 50% drop as an overreaction, highlighting the company's established, revenue-generating drug Korlym and its broader pipeline. Amidst year-end tax-loss selling and wider biotech sector volatility, community discussion centers on the potential for regulatory resolution versus further valuation adjustments.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is trending amid recent regulatory approvals for a key acquisition and an analyst firm initiating coverage with an "Overweight" rating. While some investors voice frustration over past delays in commercial revenue and management communication, a significant portion of the community maintains strong conviction in the long-term potential of its specialized isotope technology for critical sectors including advanced energy, medical applications, and next-generation computing. The conversation highlights a divide between those concerned about execution timelines and those focused on strategic asset accumulation and the company's unique market position.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending due to its recent partnership with Google Cloud for the Agentic Interop Summit, signaling increased recognition and strategic positioning within the AI ecosystem. The community is also reacting to Ocean Protocol's departure from the ASI Alliance, which has led to a significant FET token burn, viewed by many as a deflationary catalyst. Despite past volatility, investors are actively discussing Fetch.ai's potential for real-world AI agent adoption and its perceived undervaluation within the broader AI crypto sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is actively discussed after announcing plans to distribute new digital tokens to shareholders via Crypto.com. This move is generating polarized community reactions, with some investors seeing it as a potential short squeeze catalyst and shareholder reward, while others view the non-transferable tokens as a "worthless" incentive or a "pump and dump" scheme. The debate reflects ongoing concerns about the company's financial performance and future strategy.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending significantly following the FDA's Complete Response Letter to competitor Corcept Therapeutics for its Cushing's syndrome treatment. This outcome is widely viewed by the community and analysts as a "massive tailwind" for Xeris's Recorlev, strengthening its market position in a growing multi-billion dollar sector. Investors are actively discussing this enhanced competitive moat and the promising future of its XP-8121 pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Scilex Holding Company (SCLX) on Thursday said that its majority-owned subsidiary, Semnur Pharmaceuticals, and Denali Capital Acquisition Corp (DECA) have entered into a purchase agreement with an investor for a $20 million private placement.The proceeds of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://scilexholding.gcs-web.com/node/10161/pdf">agreement</a> will be used to advance the second late-stage clinical trial for the development of SP-102, a viscous gel formulation of a widely used corticosteroid for epidural injections, for the treatment of lumbosacral radicular pain. Lumbosacral radicular pain, often referred to as sciatica, is a pain that radiates along the sciatic nerve, which extends from the lower back down the leg.On Stocktwits, retail sentiment around Scilex remained within the ‘neutral’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels. <a href="https://stocktwits.com/symbol/SCLX">SCLX stock</a> is trading 0.5% lower in the pre-market session at the time of writing.<figure class="image"><img style="aspect-ratio:567/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_7_24_17_AM_png_36aea133ff.webp" alt="SCLX's Sentiment Meter and Message Volume as of 7:24 a.m. ET on Aug. 21, 2025 | Source: Stocktwits" width="567" height="60"><figcaption>SCLX's Sentiment Meter and Message Volume as of 7:24 a.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>Semnur and special purpose acquisition company (SPAC) Denali entered into a <a target="_blank" rel="noopener noreferrer nofollow" href="https://scilexholding.gcs-web.com/node/9226/pdf">plan of merger</a> on Aug. 30, 2024, for a proposed business combination, among Semnur, the SPAC, and the SPAC's unit Denali Merger Sub Inc. This provided for a pre-transaction equity value of Semnur at $2.5 billion.&nbsp;Under the deal, the combined company will be renamed Semnur Pharmaceuticals, Inc., and its common stock is expected to be listed on Nasdaq under the ticker symbol “SMNR”. The combination is now expected to close in September 2025.An investor has agreed to purchase an aggregate of 1.25 million shares of common stock of the combined company following the consummation of the merger transaction, Scilex said. The purchase price for the placement is $16.00 per share, for an aggregate purchase price of $20 million.The closing of the financing is subject to customary conditions and is expected to occur immediately following the consummation of the business combination, Scilex said.The company also said that CEO Jaisim Shah resigned as Scilex CEO and will now serve as chief executive and President of Semnur. Henry Ji, who currently serves as Executive Chairman of Scilex, was appointed as Scilex’s new CEO and President and has assumed all of the duties formerly performed by Shah, the company said.SCLX stock is up by 18% this year and down by 60% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/two-players-quietly-took-over-bitcoin-mining-power-heres-why-it-matters/chsSu9WRdi5">Two Players Quietly Took Over Bitcoin’s Mining Power — Here’s Why It Matters</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside

The proceeds of the agreement will be used to advance the second late-stage clinical trial for the development of SP-102, a viscous gel formulation of a widely used corticosteroid for epidural injections, for the treatment of lumbosacral radicular pain.

Equity

Scilex Holding Co. (SCLX), a relatively under-the-radar player in the non-opioid pain management space, has unexpectedly captured the attention of retail investors. The company experienced a staggering 41.78% increase in retail followers on Stocktwits over the past month, despite a 21% decline in its share price.However, the initial bullish sentiment has waned, with Stocktwits sentiment flipping to bearish (36/100) and message volumes surging. This shift suggests growing investor skepticism amidst recent company developments.<figure class="image"><img style="aspect-ratio:1316/306;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SCLX_Sentiment_and_message_score_Aug_1_f79a43cdac.png" alt="SCLX Sentiment and message score Aug 1.png" width="1316" height="306"><figcaption>SCLX Sentiment and message score Aug 1</figcaption></figure>The surge in retail interest can be attributed to several factors. Primarily, the announcement of a potential $2 billion deal for its subsidiary, Semnur Pharmaceuticals, to go public through a SPAC merger with Denali Capital Acquisition Corp (DECA) has generated excitement. The proceeds from this deal are earmarked for the development of SP-102, a key drug candidate in late-stage trials.Additionally, Scilex had reported preliminary Q2 net sales above estimates, indicating revenue growth. However, a significant decline in cash and cash equivalents raised concerns.The company also entered into a collaboration agreement with ACEA for the potential expansion of its ZTlido treatment, used to help relieve nerve pain after shingles, in the Greater China region.While July saw continued sales growth for ZTlido, the pace of growth slowed compared to the previous month. This, coupled with the overall bearish sentiment and declining cash reserves, seems to have tempered initial enthusiasm.With Q2 earnings report scheduled for August 9th after market hours, investors will be closely watching for further clarity on the company's financial health and the progress of its key initiatives.Photo via Vecteezy

Small-Cap Scilex Drew Biggest Jump In Retail Following For July: What Drove It?

Retail investors flocked to Scilex, drawn by news about a lucrative SPAC deal for its unit, declining cash reserves and slowing sales growth.

Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate, SP-102, is a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe lumbosacral radicular pain. The company is headquartered in Palo Alto, CA.

DECA
Denali Capital Acquisition Corp - Ordinary Shares - Class A

Feed

News

Sentiment

Fundamentals

Info

Latest DECA News

DECADenali Capital Acquisition Corp - Ordinary Shares - Class A